H2N2V1, Main, Exploration, bibRecord, 001274

CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity▿

Identifieur interne : 001274 ( Main/Exploration ); précédent : 001273; suivant : 001275

CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity▿

Auteurs : Makoto Yamashita [Japon] ; Takanori Tomozawa [Japon] ; Masayo Kakuta [Japon] ; Akane Tokumitsu [Japon] ; Hatsumi Nasu [Japon] ; Shuku Kubo [Japon]

Source :

Antimicrobial Agents and Chemotherapy [ 0066-4804 ] ; 2008.

RBID : PMC:2612152

Abstract

Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for the treatment of and prophylaxis against influenza. In this paper, the new potent NA inhibitor R-125489 is reported for the first time. R-125489 inhibited the NA activities of various type A and B influenza viruses, including subtypes N1 to N9 and oseltamivir-resistant viruses. The survival effect of R-125489 was shown to be similar to that of zanamivir when administered intranasally in a mouse influenza virus A/Puerto Rico/8/34 infection model. Moreover, we found that the esterified form of R-125489 showed improved efficacy compared to R-125489 and zanamivir, depending on the acyl chain length, and that 3-(O)-octanoyl R-125489 (CS-8958) was the best compound in terms of its life-prolonging effect (P < 0.0001, compared to zanamivir) in the same infection model. A prolonged survival effect was observed after a single administration of CS-8958, even if it was given 7 days before infection. It is suggested that intranasally administered CS-8958 works as a long-acting NA inhibitor and shows in vivo efficacy as a result of a single intranasal administration.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612152

DOI: 10.1128/AAC.00333-08
PubMed: 18955520
PubMed Central: 2612152

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity<xref ref-type="fn" rid="fn2">▿</xref>
 </title>
<author><name sortKey="Yamashita, Makoto" sort="Yamashita, Makoto" uniqKey="Yamashita M" first="Makoto" last="Yamashita">Makoto Yamashita</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tomozawa, Takanori" sort="Tomozawa, Takanori" uniqKey="Tomozawa T" first="Takanori" last="Tomozawa">Takanori Tomozawa</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kakuta, Masayo" sort="Kakuta, Masayo" uniqKey="Kakuta M" first="Masayo" last="Kakuta">Masayo Kakuta</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tokumitsu, Akane" sort="Tokumitsu, Akane" uniqKey="Tokumitsu A" first="Akane" last="Tokumitsu">Akane Tokumitsu</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nasu, Hatsumi" sort="Nasu, Hatsumi" uniqKey="Nasu H" first="Hatsumi" last="Nasu">Hatsumi Nasu</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kubo, Shuku" sort="Kubo, Shuku" uniqKey="Kubo S" first="Shuku" last="Kubo">Shuku Kubo</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">18955520</idno>
<idno type="pmc">2612152</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612152</idno>
<idno type="RBID">PMC:2612152</idno>
<idno type="doi">10.1128/AAC.00333-08</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">000261</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000261</idno>
<idno type="wicri:Area/Pmc/Curation">000261</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000261</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000B36</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B36</idno>
<idno type="wicri:Area/Ncbi/Merge">000334</idno>
<idno type="wicri:Area/Ncbi/Curation">000334</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000334</idno>
<idno type="wicri:doubleKey">0066-4804:2008:Yamashita M:cs:a:prodrug</idno>
<idno type="wicri:Area/Main/Merge">001287</idno>
<idno type="wicri:Area/Main/Curation">001274</idno>
<idno type="wicri:Area/Main/Exploration">001274</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity<xref ref-type="fn" rid="fn2">▿</xref>
 </title>
<author><name sortKey="Yamashita, Makoto" sort="Yamashita, Makoto" uniqKey="Yamashita M" first="Makoto" last="Yamashita">Makoto Yamashita</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tomozawa, Takanori" sort="Tomozawa, Takanori" uniqKey="Tomozawa T" first="Takanori" last="Tomozawa">Takanori Tomozawa</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kakuta, Masayo" sort="Kakuta, Masayo" uniqKey="Kakuta M" first="Masayo" last="Kakuta">Masayo Kakuta</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tokumitsu, Akane" sort="Tokumitsu, Akane" uniqKey="Tokumitsu A" first="Akane" last="Tokumitsu">Akane Tokumitsu</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nasu, Hatsumi" sort="Nasu, Hatsumi" uniqKey="Nasu H" first="Hatsumi" last="Nasu">Hatsumi Nasu</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kubo, Shuku" sort="Kubo, Shuku" uniqKey="Kubo S" first="Shuku" last="Kubo">Shuku Kubo</name>
<affiliation wicri:level="1"><nlm:aff id="aff0">Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Biological Research Laboratories IV, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial Agents and Chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for the treatment of and prophylaxis against influenza. In this paper, the new potent NA inhibitor R-125489 is reported for the first time. R-125489 inhibited the NA activities of various type A and B influenza viruses, including subtypes N1 to N9 and oseltamivir-resistant viruses. The survival effect of R-125489 was shown to be similar to that of zanamivir when administered intranasally in a mouse influenza virus A/Puerto Rico/8/34 infection model. Moreover, we found that the esterified form of R-125489 showed improved efficacy compared to R-125489 and zanamivir, depending on the acyl chain length, and that 3-(<italic>O</italic>
)-octanoyl R-125489 (CS-8958) was the best compound in terms of its life-prolonging effect (<italic>P</italic>
 < 0.0001, compared to zanamivir) in the same infection model. A prolonged survival effect was observed after a single administration of CS-8958, even if it was given 7 days before infection. It is suggested that intranasally administered CS-8958 works as a long-acting NA inhibitor and shows in vivo efficacy as a result of a single intranasal administration.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Yamashita, Makoto" sort="Yamashita, Makoto" uniqKey="Yamashita M" first="Makoto" last="Yamashita">Makoto Yamashita</name>
</region>
<name sortKey="Kakuta, Masayo" sort="Kakuta, Masayo" uniqKey="Kakuta M" first="Masayo" last="Kakuta">Masayo Kakuta</name>
<name sortKey="Kubo, Shuku" sort="Kubo, Shuku" uniqKey="Kubo S" first="Shuku" last="Kubo">Shuku Kubo</name>
<name sortKey="Nasu, Hatsumi" sort="Nasu, Hatsumi" uniqKey="Nasu H" first="Hatsumi" last="Nasu">Hatsumi Nasu</name>
<name sortKey="Tokumitsu, Akane" sort="Tokumitsu, Akane" uniqKey="Tokumitsu A" first="Akane" last="Tokumitsu">Akane Tokumitsu</name>
<name sortKey="Tomozawa, Takanori" sort="Tomozawa, Takanori" uniqKey="Tomozawa T" first="Takanori" last="Tomozawa">Takanori Tomozawa</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001274 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001274 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:2612152
   |texte=   CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity▿ 
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:18955520" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

Serveur d'exploration H2N2

CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity▿

CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity▿

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.